Ajuts a la recerca

Bayer Grants4Targets

Organisme

Grants4Targets - Bayer Health Care

Objecte

Grants4Targets fund the exploration of attractive, novel drug targets in the fields of oncology, gynecology, cardiology, hematology.

Descripció

Awards
   Support Grants: 5.000 € to 10.000 € to further advance research on targets that are at a very early stage of discovery.

   Focus Grants: 10.000 € to 125.000 € for more mature ideas, e.g. to address specific aspects of a target as a first step towards transferring it to the drug discovery process.

In addition to the financial support, successful applicants may benefit from the complementary expertise by providing tools and/or investigations, including:
 

-Antibodies

-Small Molecule Tool Compounds

-Biobank samples

-Technologies

-The size of the individual grant will depend on the target specifics and the phase of validation.


 

There are two advantages in the program. The first being the speed with which the grant is funded. The second being the potential of further collaboration in the future to advance the common research interests between my laboratory and Bayer.
 

Indications, treatment paradigms and approaches
 

Fields and focus
 

• Oncology: anti-proliferative, survival signaling, transcription and chromatin modulation, cell cycle regulation, tumor metabolism, hypoxia, immunotherapy and antibody-drug conjugates.
• Gynecology: novel treatment options for endometriosis (incl. adenomyosis uteri/endometriosis interna) and uterine fibroids (uterine leiomyoma).
• Cardiology: novel approaches to the care of chronic and/or acute pulmonary hypertension, atrial fibrillation, heart failure, acute coronary syndrome, ischemic stroke, peripheral arterial occlusive disease, acute lung injury/adult respiratory distress syndrome, cardiorenal syndrome and chronic kidney diseases.
• Hematology: hemophelia, anemia and thrombocytopenia.

Drug target

-The definition of a "druggable" target as a nucleic acid or a protein (e.g. an enzyme, a receptor) whose activity can be modified by a drug.

-The drug can be a small-molecular-weight chemical compound or a biological, such as an antibody or a recombinant protein. The target should have been shown to be effective/mechanistically involved in the disease by relevant in vitro or in vivo models.
 

Disease-related biomarker

A disease-related biomarker might be a protein, a nucleic acid or a metabolite that can be measured in biological fluids, tissue or isolated cells for the diagnosis, monitoring, prognosis or stratification of patients.

Information generated by such biomarkers may enable intervention at an earlier and potentially more curable stage of the disease than under usual clinical diagnostic conditions or may allow the monitoring of a therapeutic action on disease progression as opposed/or in addition to the classical signs and symptoms.
 

Termini oficial

Annual deadlines for submission are March 31 and August 31.

Termini IISPV

Cal comunicar abans del 25 de febrer de 2013 que es vol participar a la convocatòria, enviant un e-mail a convocatories@iispv.cat . Termini: 25 de Març de 2013

Pujar